Article

Targeted therapies inhibit PCa bone metastasis

San Francisco-Prostate cancer bone metastases appear to react favorablyto treatment with a new bisphosphonate and the tyrosine-kinase inhibitorsPKI-166 and STI-571, according to studies presented at the American Associationfor Cancer Research annual meeting here.

Related Content
© 2025 MJH Life Sciences

All rights reserved.